Viral vectors have a long track record in therapeutic gene delivery and intervention. Current efforts are starting to bear fruit, as more viral vector therapies are reaching the later stages of clinical development. Since the discovery of adeno-associated virus (AAV), a variety of serotypes and variants have been described and characterized, with AAV2 being the most widely studied.